Patents by Inventor Francis Volz

Francis Volz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7741493
    Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: June 22, 2010
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Patrick Shum, Alexandre Gross, Liang Ma, Daniel G. McGarry, Gregory H. Merriman, David Rampe, Garth Ringheim, Jeffrey Stephen Sabol, Francis A. Volz
  • Publication number: 20080132550
    Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.
    Type: Application
    Filed: November 29, 2007
    Publication date: June 5, 2008
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Patrick SHUM, Alexandre GROSS, Liang MA, Daniel G. MCGARRY, Gregory H. MERRIMAN, David RAMPE, Garth RINGHEIM, Jeffrey Stephen SABOL, Francis A. VOLZ
  • Patent number: 7326792
    Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: February 5, 2008
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Patrick Shum, Alexandre Gross, Liang Ma, Daniel G. McGarry, Gregory H. Merriman, David Rampe, Garth Ringheim, Jeffrey Stephen Sabol, Francis A. Volz
  • Publication number: 20050026916
    Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.
    Type: Application
    Filed: July 21, 2004
    Publication date: February 3, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Patrick Shum, Alexandre Gross, Liang Ma, Daniel McGarry, Gregory Merriman, David Rampe, Garth Ringheim, Jeffrey Sabol, Francis Volz
  • Publication number: 20030153604
    Abstract: This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.
    Type: Application
    Filed: February 24, 2003
    Publication date: August 14, 2003
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: William P. Dankulich, Daniel G. McGarry, Christopher Burns, Timothy F. Gallagher, Francis A. Volz
  • Patent number: 6599918
    Abstract: This invention is directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans that inhibit Factor Xa, pharmaceutical compositions comprising these compounds and their use for inhibiting Factor Xa or treating pathological conditions in a patient that may be ameliorated by administration of such compounds. This invention is also is also directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans which directly inhibit both Factor Xa and Factor IIa (thrombin), to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of simultaneously directly inhibiting both Factor Xa and Factor IIa (thrombin).
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: July 29, 2003
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Christopher J. Burns, William P. Dankulich, Daniel G. McGarry, Francis A. Volz
  • Patent number: 6541505
    Abstract: This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: April 1, 2003
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: William P. Dankulich, Daniel G. McGarry, Christopher Burns, Timothy F. Gallagher, Francis A. Volz
  • Publication number: 20020193410
    Abstract: This invention is directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans that inhibit Factor Xa, pharmaceutical compositions comprising these compounds and their use for inhibiting Factor Xa or treating pathological conditions in a patient that may be ameliorated by administration of such compounds. This invention is also is also directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans which directly inhibit both Factor Xa and Factor IIa (thrombin), to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of simultaneously directly inhibiting both Factor Xa and Factor IIa (thrombin).
    Type: Application
    Filed: February 22, 2002
    Publication date: December 19, 2002
    Inventors: Christopher J. Burns, William P. Dankulich, Daniel G. McGarry, Francis A. Volz
  • Patent number: 5216015
    Abstract: This invention relates to compounds which are steroidyl derivatives of 4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one and the corresponding ring-opened hydroxy acid form thereof which are useful as antihypercholesterolemic agents, to pharmaceutical compositions including such compounds, and to their use in treating hypercholesterolemia.
    Type: Grant
    Filed: February 5, 1991
    Date of Patent: June 1, 1993
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Daniel G. McGarry, Francis A. Volz, John R. Regan, Michael N. Chang